A Multi-center, Randomized, Double-Blind, Parallel Comparative, Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin Versus Levofloxain in Treating Adult Patients With CAP

Trial Profile

A Multi-center, Randomized, Double-Blind, Parallel Comparative, Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin Versus Levofloxain in Treating Adult Patients With CAP

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs Nemonoxacin (Primary) ; Levofloxacin
  • Indications Community-acquired pneumonia
  • Focus Registrational; Therapeutic Use
  • Sponsors TaiGen Biotechnology
  • Most Recent Events

    • 12 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 30 May 2017 According to a company media release, TaiGen Biotechnology has submitted a New Drug Application (NDA) for the intravenous formulation of Taigexyn (Nemonoxacin) to the China Food and Drug Administration (CFDA). The NDA submission was supported by the results of this trial.
    • 11 Jan 2016 Planned number of patients changed from 540 to 603, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top